Search Results | Blood | American Society of Hematology

1-20 of 111

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Drugs

Clinical Trials & Observations

Charles J. Milrod, Frances R Blevins, David Hughes, Adam Lerner, Shayna Sarosiek, Vaishali Sanchorawala, J. Mark Sloan

Blood blood.2021010853.

DOI: https://doi.org/10.1182/blood.2021010853

Published: 2021

Includes: Supplemental data

Journal Articles

Modified High Dose Versus High Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis

Camille V Edwards, MD, Dina Brauneis, ANP, Karen Quillen, MDMPH, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 4–5.

DOI: https://doi.org/10.1182/blood-2020-141560

Published: 2020

Journal Articles

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Blood (2020) 136 (Supplement 1): 1–2.

DOI: https://doi.org/10.1182/blood-2020-141549

Published: 2020

Journal Articles

Amyloidosis Appointment Companion: A Virtual Healthcare Tool to Optimize Shared Decision Making and Improve Patient Experience and Provider Satisfaction for Telehealth and in-Person Appointments

Isabelle Lousada, Robyn Himick, Jason Shore, Adam Sodowick, Lisa M Mendelson, ANP, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 38–39.

DOI: https://doi.org/10.1182/blood-2020-139956

Published: 2020

Journal Articles

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey

Paolo Milani, MDPhD, Vaishali Sanchorawala, MD, Ramon Lecumberri, MD PhD, Sunil Saith, MD, Mathew S. Maurer, MD, M. Teresa Cibeira, MD PhD, Giampaolo Merlini, MD, Stefan Schönland, MD, Giovanni Palladini, MD PhD

Blood (2020) 136 (Supplement 1): 11.

DOI: https://doi.org/10.1182/blood-2020-141569

Published: 2020

Journal Articles

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications

Frances Blevins, PA-C, David Hughes, PharmD, Charles Milrod, MD, Preya Patel, MD, Shayna DeMari, BA, Adam Lerner, MD, Shayna Sarosiek, MD, Vaishali Sanchorawala, MD, John Mark Sloan, MD

Blood (2020) 136 (Supplement 1): 23–24.

DOI: https://doi.org/10.1182/blood-2020-136775

Published: 2020

Journal Articles

Early Serum Free Light Chain Response after High-Dose Melphalan and Stem Cell Transplantation Predicts Hematologic Response in AL Amyloidosis

Vanessa Fiorini Furtado, MD, Dina Brauneis, ANP, Shayna Sarosiek, MD, Karen Quillen, MDMPH, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 26.

DOI: https://doi.org/10.1182/blood-2020-138500

Published: 2020

Journal Articles

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Terri L. Parker, MD, Adam Rosenthal, MS, Vaishali Sanchorawala, MD, Heather J Landau, MD, Erica Campagnaro, MD, Prashant Kapoor, MD, Natalia Neparidze, MD, Patrick Hagen, MD, Shayna Sarosiek, MD, Emma C. Scott, MD, Antje Hoering, PhD, Brian G.M. Durie, MD, Saad Z. Usmani, MDMBBS,MBA, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

DOI: https://doi.org/10.1182/blood-2020-143180

Published: 2020

Journal Articles

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 37–40.

DOI: https://doi.org/10.1182/blood-2020-139438

Published: 2020

Journal Articles

Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes

Andrew Staron, Lawreen H Connors, PhD, Luke Zheng, BS, Gheorghe Doros, PhD, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 51.

DOI: https://doi.org/10.1182/blood-2020-139751

Published: 2020

Journal Articles

Reduction in Absolute Involved Free Light Chain and Difference between Involved and Uninvolved Free Light Chain Is Associated with Prolonged Major Organ Deterioration Progression-Free Survival in Patients with Newly Diagnosed AL Amyloidosis Receiving Bortezomib, Cyclophosphamide, and Dexamethasone with or without Daratumumab: Results from Andromeda

Blood (2020) 136 (Supplement 1): 48–50.

DOI: https://doi.org/10.1182/blood-2020-137582

Published: 2020

Journal Articles

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

David Hughes, PharmD, Radhika Jhaveri, PharmD, Bhavesh Shah, RPh, Frances Blevins, PA-C, Alexamil Rodriguez, CPhT, Shayna Sarosiek, MD, Adam Lerner, MD, John Mark Sloan, MD, Vaishali Sanchorawala, MD

Blood (2020) 136 (Supplement 1): 42–43.

DOI: https://doi.org/10.1182/blood-2020-135992

Published: 2020

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Clinical Trials & Observations

Blood (2020) 136 (1): 71–80.

DOI: https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

Clinical Trials & Observations

Vaishali Sanchorawala, Shayna Sarosiek, Amanda Schulman, Meredith Mistark, Mary Ellen Migre, Ramon Cruz, J. Mark Sloan, Dina Brauneis, Anthony C. Shelton

Blood (2020) 135 (18): 1541–1547.

DOI: https://doi.org/10.1182/blood.2019004436

Published: 2020

Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 3163.

DOI: https://doi.org/10.1182/blood-2019-124244

Published: 2019

Journal Articles

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Angela Dispenzieri, MD, Eftathios Kastritis, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM, Stefan O. Schönland, MD, Kihyun Kim, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD, Fiona Kwok, FRACP,FRCPA,MBBS, Kenshi Suzuki, MD PhD, Raymond L Comenzo, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Douglas V. Faller, MD PhD, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 139.

DOI: https://doi.org/10.1182/blood-2019-124409

Published: 2019

Journal Articles

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Morie A Gertz, MD, Adam D. Cohen, MD, Raymond L Comenzo, MD, Charles Du Mond, Eftathios Kastritis, Heather J Landau, MD, Edward N. Libby, III, MD, Michaela Liedtke, MD, Giampaolo Merlini, MD, Vaishali Sanchorawala, MD, Stefan O. Schönland, MD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Jeffrey A. Zonder, Gene Kinney, PhD

Blood (2019) 134 (Supplement_1): 3166.

DOI: https://doi.org/10.1182/blood-2019-124482

Published: 2019

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

DOI: https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Shayna Sarosiek, Vaishali Sanchorawala, MD, Mariateresa Fulcinti, Allison P. Jacob, Nikhil C. Munshi, MD, Cindy Varga, MD BSc

Blood (2019) 134 (Supplement_1): 4353.

DOI: https://doi.org/10.1182/blood-2019-131863

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Jose Acevedo, Gheorghe Doros, PhD, Raphael Szalat, John Mark Sloan, MD, Shayna Sarosiek, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 5447.

DOI: https://doi.org/10.1182/blood-2019-124980

Published: 2019

2 3 4 5

NARROW

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Drugs

Modified High Dose Versus High Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis

A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts

Amyloidosis Appointment Companion: A Virtual Healthcare Tool to Optimize Shared Decision Making and Improve Patient Experience and Provider Satisfaction for Telehealth and in-Person Appointments

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey

Incidence of Skin Hyperpigmentation in Black Patients Receiving Treatment with Immunomodulatory Medications

Early Serum Free Light Chain Response after High-Dose Melphalan and Stem Cell Transplantation Predicts Hematologic Response in AL Amyloidosis

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Health-Related Quality of Life in Patients with AL Amyloidosis Treated with Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone: Results from the Phase 3 Andromeda Study

Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

The Use of Next Generation Gene Sequencing to Measure Minimal Residual Disease in Patients with AL Amyloidosis and Low Plasma Cell Burden: A Feasibility Study

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only